Clinical Validation of Pharmacopoeal Formulation Sunoon-e-Mukhrij-e-Rutubat for symptomatic relief in Lissa-e-Damiya (Bleeding gums).

Central Council For Research In Unani Medicine0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Patients of either sex in the age group 18-65 years.
•2. Patients having Lissa-e-Damiya (Bleeding gums) with or without any of the following symptoms:
•Painful chewing
•Waram al-Lissa (Gingival swelling)
•Humra al-Lissa (Gingival erythema)
•Dhahab Maâ?? al-Asnan (Sensitive teeth)

•1. Bleeding gums accompanied by impaired neurological functions (loss of balance, weakness, numbness, or speech disturbances), double vision, seizures, mental disturbances, and loss of consciousness.
•2. Bleeding gums accompanied by persistent nausea, vomiting, fever and stiff neck.
•3. Presence of a periodontal abscess as diagnosed from clinical examination of the bleeding gums.
•4. Presence of concomitant bleeding due to any other condition such as soft-tissue lesions (e.g., aphthous/ traumatic ulcer, herpes labialis, acute necrotizing ulcerative gingivitis) or multiple hard-tissue (e.g., carious).
•5. Known case of Hemophilia, Low platelet count (thrombocytopenia) and von Willebrand disease (VWD) etc.
•6. History or clinical evidence of chronic diseases requiring long-term treatment, e.g., DM, hypertension, tuberculosis, HIV etc
•7. Pregnant and lactating women.
•8. History of Hypersensitivity to the study drug or any of its ingredients.
•9. History of addiction (alcohol, drugs,tobacco)

发起方